Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis

Table 2

Comparison of treatments and response in GCLM between the AFP ≥ 20 ng/ml group and AFP < 20 ng/ml group.

Variables	AFP ≥ 20 ng/ml	AFP < 20 ng/ml
First-line chemotherapy regimens
Platinum-based doublet regimen	46 (62.2%)	156 (63.7%)	0.325
Taxane-based doublet regimen	13 (17.6%)	44 (18.0%)
Triplet regimen	9 (12.2%)	17 (6.9%)
Single-drug regimen	6 (8.1%)	19 (7.8%)
Others	0 (0.0%)	9 (3.7%)
Response of first-line chemotherapy
PR	28 (41.2%)	106 (56.1%)	0.024
SD + PD	40 (58.8%)	83 (43.9%)
Subsequent therapies after the first-line chemo
Second-line chemotherapy
Yes	24 (40.0%)	97 (53.0%)	0.055
No	36 (60.0%)	86 (47.0%)
Surgery treatment
Yes	1 (1.4%)	8 (3.3%)	0.344
No	73 (98.6%)	237 (96.7%)
Local treatment of LM^a
Yes	23 (31.1%)	60 (24.5%)	0.163
No	51 (68.9%)	185 (75.5%)

^aIncluding TACE, ablation, radiotherapy, and liver resection. PR = partial response; SD = stable disease; PD = progressive disease; TACE = transcatheter arterial chemoembolization.